Document is current
Any future updates will be listed below
-
Authors
Maiorino, Maria Ida https://orcid.org/0000-0003-4659-7546
Gesualdo, Carlo https://orcid.org/0000-0003-4955-7857
Angelino, Silvia https://orcid.org/0009-0008-1503-6918
Rossi, Settimio https://orcid.org/0000-0002-8682-6860
Di Martino, Nicole https://orcid.org/0009-0001-8062-3958
Iodice, Clemente https://orcid.org/0000-0003-1688-6646
Longo, Miriam https://orcid.org/0000-0002-6459-5854
Scappaticcio, Lorenzo https://orcid.org/0000-0003-2972-9551
Bellastella, Giuseppe https://orcid.org/0000-0002-4748-321X
Simonelli, Francesca https://orcid.org/0000-0001-8520-6769
Esposito, Katherine https://orcid.org/0000-0002-3652-5154
-
Funding
Funding for this research was provided by:
Università degli Studi della Campania Luigi Vanvitelli
- License Information
-
More Information
Article History
Received: 4 January 2026
Accepted: 6 May 2026
First Online: 4 June 2026
Declarations
:
: MIM has given lectures for Eli Lilly and Sanofi. KE received a consultancy fee from Eli Lilly and GSK and has given lectures from Eli Lilly, Sanofi, Novo Nordisk, Roche and Bayer. No other potential conflicts of interest relevant to this article were reported.
: Study protocol was approved by the Medical Ethics Committee of University of Campania “Luigi Vanvitelli” (Prot. 0003239/I, 01/02/2023). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants included in the study.
